Browsing Tag
Venetoclax
5 posts
Can fixed-duration oral therapy finally replace indefinite CLL treatment? AstraZeneca’s FDA win explains why
FDA approval of AstraZeneca’s CALQUENCE plus venetoclax introduces a fixed-duration oral option for frontline CLL. Find out why this matters for patients and investors.
Aptevo Therapeutics achieves major breakthrough with mipletamig in acute myeloid leukemia
Aptevo Therapeutics has unveiled remarkable findings from Cohort 1 of its RAINIER clinical trial for mipletamig, a bispecific…
OncoVerity accelerates AML treatment with Series A extension
OncoVerity, a leader in integrating bioinformatics with oncology drug development, has closed a Series A extension financing round,…
AbbVie’s ibrutinib, venetoclax combo succeeds in phase 3 GLOW study
AbbVie said that the phase 3 GLOW study in chronic lymphocytic leukemia (CLL) investigating the combination of IMBRUVICA…
Tolero Pharmaceuticals and AbbVie collaborate to advance AML treatment
Tolero Pharmaceuticals has entered into a clinical research collaboration with AbbVie to explore the potential of combining their…